As a monoclonal antibody targeting HER2, trastuzumab has been recognized as the foundational medication in HER2-positive breast cancer treatment and provided remarkable clinical benefits for numerous patients (Marra et al., 2024). This evidence concerns the gene ERBB2 and breast carcinoma.